A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples.

In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.

• respiratory failure;
• hip fracture;
• Injury Severity Score no higher than 8 points.

Exclusion Criteria:

• All contraindications for use of the device:
• terminal condition of the patient;
• shock;
• paradoxical pathological breathing;
• hypertensive crisis;
• severe hypocoagulation with a risk of hematoma formation or bleeding in the projection of exposure;
• severe hypercoagulation, risk of thrombus/embolus migration along the main vessels in the area of exposure;
• acute cerebrovascular accident in the first 1-3 days;
• brain edema;
• presence of multiple purulent or burn wound surfaces in the area of exposure;
• presence of unstable rib fractures;
• pneumomediastinum and/or subcutaneous emphysema of the chest;
• osteomyelitis of the ribs and/or thoracic spine;
• spinal fracture without orthopedic fixation;
• chest or abdominal trauma with bleeding;
• Injury Severity Score greater than 8 points;
• concomitant diseases in the stage of decompensation.